Oncology  Video

ER+ metastatic breast cancer: Elacestrant and beyond

Follow a patient's journey during and post-elacestrant treatment for ER+/HER2- metastatic breast cancer

Prof. Maria Vittoria Dieci

Prof. Maria Vittoria Dieci

Publication Date

Feb 2024

menu

In this second patient case video from BREAST CANCER CONNECT, Prof. Maria Vittoria Dieci delves into the continuation of a patient case with ER+/HER2- metastatic breast cancer initially presented in our first video of this series.

Throughout this journey, we'll explore what to expect after prescribing elacestrant and take a closer look at patient-reported outcomes in the EMERALD trial.

Catch up on the first video to hear Prof Francois-Clement Bidard discuss how to optimise treatment selection and make appropriate sequencing decisions for patients with ER+/HER2- metastatic breast cancer.

Clinical Takeaways

  • PROs results demonstrating no difference between treatment arms in the EMERALD trial, support elacestrant as a clinically meaningful option in this setting

  • Elacestrant has a manageable safety profile

  • If a patient progresses on elacestrant, the choice of subsequent therapy line should be based on multiple factors, including sensitivity to prior treatments, disease burden, and tumour biology. In this context, ADCs represent a new option

  • Recognise the efficacy and safety profiles of SERDs for patients with advanced or metastatic BC, and understand their place in the treatment landscape for patients with BC
  • Implement optimization of treatment selection, and make the appropriate sequencing decisions
  • Be able to identify and manage adverse events

Maria Vittoria Dieci, MD, is Associate Professor at the University of Padova, vice-director of the Specialization School in Medical Oncology at the same University and attending physician at the Division of Oncology 2 of the Istituto Oncologico Veneto in Padova. She specialised in Oncology in March 2012 at the University of Modena. From May 2012 to November 2013 she completed a 18-month-research experience at the Translational Research Unit (INSERM U981) of the Gustave Roussy Institute (Villejuif, France), and obtained the “Diplome Universitaire Européen en Recherche Translationnelle et Clinique en Cancérologie”. Since November 2013 she has been conducting research and clinical activity in the field of breast cancer at the University of Padova / Istituto Oncologico Veneto IRCCS.

She is panelist of the Breast Cancer Guidelines by the Italian Association of Medical Oncology. Prof Dieci’s research production from 2008 up till now consists of more than 140 papers in peer-reviewed journals.

Prof. Maria Vittoria Dieci has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Eli Lilly, Pfizer, Novartis, Roche, Exact Science, Daiichi Sankyo, Gilead, Seagen.
Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology.
Endorsement
GRASP
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology.

Meet the experts Independent IME approved

Other programmes of interest

video Video
Oncology 
Recent advances in precision oncology and future implications

Two emerging and two established targets

Experts
Prof. David Hong
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024
PRECISION ONCOLOGY CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Survey on the evolving role of the oncology nurse in the USA

Announcing the publication of survey results 

Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo
  • download Downloadable
    Resources
  • clock 10 MIN
  • calendar Dec 2024
GI NURSES CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Bayer.
video Video
Oncology 
Elacestrant in ER+/HER2- metastatic breast cancer

An expert overview of the EMERALD subgroup analysis

Experts
Dr Virginia Kaklamani
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024
COR2ED
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
video Video
Oncology 
Systemic treatment options for patients with non-clear cell renal cell carcinoma (nccRCC)

Managing patients with nccRCC: guidelines, recommendations, and best practice

Experts
Prof. Laurence Albiges
Endorsed by
Urobel VZW | ASBL
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024
GU CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Eisai Europe Limited (“Eisai”). Eisai has had no input on the educational content of, or speakers involved in this programme. 
micro-learning Micro learning
Oncology 
Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

Risk factors, diagnostic tools and treatment options for different patient groups

Experts
Prof. Efrat Dotan, Prof. Shubham Pant
Endorsed by
Digestive Cancers Europe
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024
GI CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Ipsen USA.
conference-update Conference update
Oncology 
Rezatapopt in TP53 Y220C mutated metastatic breast cancer: PYNNACLE phase 1/2 update

Exploring emerging treatment strategies presented at SABCS 2024

Experts
Prof. Frédérique Penault-Llorca, Dr Ecaterina E Dumbrava
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Dec 2024
COR2ED
This programme has been sponsored by PMV Pharma.
Explore all programmes